Fresenius SE Pre-Tax Profit Margin 2016-2024 | FSNUY
Current and historical pre-tax profit margin for Fresenius SE (FSNUY) from 2016 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Fresenius SE pre-tax profit margin for the three months ending September 30, 2024 was .
| Fresenius SE Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2024-09-30 |
$13.83B |
$0.53B |
3.81% |
| 2024-06-30 |
$13.94B |
$0.34B |
2.43% |
| 2024-03-31 |
$19.35B |
$0.56B |
2.89% |
| 2023-12-31 |
$24.13B |
$0.77B |
3.20% |
| 2023-09-30 |
$39.20B |
$1.88B |
4.79% |
| 2023-06-30 |
$43.73B |
$2.36B |
5.40% |
| 2023-03-31 |
$43.10B |
$2.75B |
6.37% |
| 2022-12-31 |
$43.03B |
$2.97B |
6.89% |
| 2022-09-30 |
$43.53B |
$3.56B |
8.17% |
| 2022-06-30 |
$43.99B |
$3.85B |
8.74% |
| 2022-03-31 |
$44.47B |
$4.15B |
9.34% |
| 2021-12-31 |
$44.39B |
$4.32B |
9.73% |
| 2021-09-30 |
$44.08B |
$4.21B |
9.56% |
| 2021-06-30 |
$43.51B |
$4.30B |
9.87% |
| 2021-03-31 |
$42.19B |
$4.26B |
10.11% |
| 2020-12-31 |
$41.44B |
$4.26B |
10.27% |
| 2020-09-30 |
$40.66B |
$4.42B |
10.87% |
| 2020-06-30 |
$40.06B |
$4.36B |
10.89% |
| 2020-03-31 |
$40.09B |
$4.36B |
10.88% |
| 2019-12-31 |
$39.66B |
$4.38B |
11.04% |
| 2019-09-30 |
$39.42B |
$4.42B |
11.21% |
| 2019-06-30 |
$39.12B |
$4.40B |
11.24% |
| 2019-03-31 |
$39.27B |
$5.48B |
13.94% |
| 2018-12-31 |
$39.60B |
$5.51B |
13.91% |
| 2018-09-30 |
$39.76B |
$5.38B |
13.52% |
| 2018-06-30 |
$39.98B |
$5.45B |
13.63% |
| 2018-03-31 |
$39.37B |
$4.41B |
11.21% |
| 2017-12-31 |
$38.30B |
$4.45B |
11.62% |
| 2017-09-30 |
$36.47B |
$4.53B |
12.41% |
| 2017-06-30 |
$34.84B |
$4.45B |
12.76% |
| 2017-03-31 |
$33.47B |
$4.38B |
13.10% |
| 2016-12-31 |
$32.18B |
$4.14B |
12.88% |
| 2016-09-30 |
$31.71B |
$10.91B |
34.41% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$21.703B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
